IOM Report Urges FDA Shift from 510(k) Program

FDA is displeased with a new report from the IOM that recommends replacing the 510(k) program with a new one that blends pre-market and post-market review processes.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories